Literature DB >> 12153825

Elevated intrasynaptic dopamine release in Tourette's syndrome measured by PET.

Harvey S Singer1, Sally Szymanski, Joseph Giuliano, Fuji Yokoi, A Semih Dogan, James R Brasic, Yun Zhou, Anthony A Grace, Dean F Wong.   

Abstract

OBJECTIVE: Dopaminergic abnormalities in frontal-subcortical circuits have been hypothesized as the underlying pathophysiologic mechanism in Tourette's syndrome. The objective of this study was to test the hypothesis that presynaptic dopamine release from the striatum is abnormal in adults with Tourette's syndrome.
METHOD: Seven adults with Tourette's syndrome and five age-matched comparison subjects each received two positron emission tomography (PET) scans with high specific activity [11C]raclopride. The first scan followed an intravenous injection of saline; the second followed an intravenous injection of amphetamine. The relative dopamine release was estimated as the percentage difference in binding potential between the postsaline and postamphetamine scans.
RESULTS: Binding potential determined after the initial [11C]raclopride scan did not significantly differ between Tourette's syndrome and comparison subjects. After amphetamine challenge, the mean value of intrasynaptic dopamine in the putamen (as determined by true equilibrium bolus estimation) increased by 21% in the subjects with Tourette's syndrome and did not change in the comparison subjects; the mean values increased by 16.9% and decreased by 1.8%, respectively, when measured by the constrained method. Dopamine release in the caudate region was not significantly different in the Tourette's syndrome and comparison subjects.
CONCLUSIONS: Greater putamen dopamine release was seen in adults with Tourette's syndrome than in comparison subjects after a pharmacologic challenge with amphetamine. These results suggest that the underlying pathobiology in Tourette's syndrome is a phasic dysfunction of dopamine transmission.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12153825     DOI: 10.1176/appi.ajp.159.8.1329

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  58 in total

Review 1.  Neurobiological substrates of Tourette's disorder.

Authors:  James F Leckman; Michael H Bloch; Megan E Smith; Daouia Larabi; Michelle Hampson
Journal:  J Child Adolesc Psychopharmacol       Date:  2010-08       Impact factor: 2.576

2.  Dopamine receptor modulation of repetitive grooming actions in the rat: potential relevance for Tourette syndrome.

Authors:  Jennifer L Taylor; Abha K Rajbhandari; Kent C Berridge; J Wayne Aldridge
Journal:  Brain Res       Date:  2010-01-28       Impact factor: 3.252

3.  Hypothesizing dopaminergic genetic antecedents in schizophrenia and substance seeking behavior.

Authors:  Kenneth Blum; Marlene Oscar-Berman; Rajendra D Badgaiyan; Tomas Palomo; Mark S Gold
Journal:  Med Hypotheses       Date:  2014-02-26       Impact factor: 1.538

Review 4.  Mouse models of neurodevelopmental disease of the basal ganglia and associated circuits.

Authors:  Samuel S Pappas; Daniel K Leventhal; Roger L Albin; William T Dauer
Journal:  Curr Top Dev Biol       Date:  2014       Impact factor: 4.897

5.  Mechanisms of dopaminergic and serotonergic neurotransmission in Tourette syndrome: clues from an in vivo neurochemistry study with PET.

Authors:  Dean F Wong; James R Brasić; Harvey S Singer; David J Schretlen; Hiroto Kuwabara; Yun Zhou; Ayon Nandi; Marika A Maris; Mohab Alexander; Weiguo Ye; Olivier Rousset; Anil Kumar; Zsolt Szabo; Albert Gjedde; Anthony A Grace
Journal:  Neuropsychopharmacology       Date:  2007-11-07       Impact factor: 7.853

Review 6.  Genetic susceptibility and neurotransmitters in Tourette syndrome.

Authors:  Peristera Paschou; Thomas V Fernandez; Frank Sharp; Gary A Heiman; Pieter J Hoekstra
Journal:  Int Rev Neurobiol       Date:  2013       Impact factor: 3.230

7.  Decreased number of parvalbumin and cholinergic interneurons in the striatum of individuals with Tourette syndrome.

Authors:  Yuko Kataoka; Paul S A Kalanithi; Heidi Grantz; Michael L Schwartz; Clifford Saper; James F Leckman; Flora M Vaccarino
Journal:  J Comp Neurol       Date:  2010-02-01       Impact factor: 3.215

Review 8.  Neurogenetics of dopaminergic receptor supersensitivity in activation of brain reward circuitry and relapse: proposing "deprivation-amplification relapse therapy" (DART).

Authors:  Kenneth Blum; Thomas J H Chen; B William Downs; Abdalla Bowirrat; Roger L Waite; Eric R Braverman; Margaret Madigan; Marlene Oscar-Berman; Nicholas DiNubile; Eric Stice; John Giordano; Siobhan Morse; Mark Gold
Journal:  Postgrad Med       Date:  2009-11       Impact factor: 3.840

Review 9.  Immunopathogenic mechanisms in tourette syndrome: A critical review.

Authors:  Davide Martino; Russell C Dale; Donald L Gilbert; Gavin Giovannoni; James F Leckman
Journal:  Mov Disord       Date:  2009-07-15       Impact factor: 10.338

10.  New therapeutic approach to Tourette Syndrome in children based on a randomized placebo-controlled double-blind phase IV study of the effectiveness and safety of magnesium and vitamin B6.

Authors:  Rafael Garcia-Lopez; Emilio Perea-Milla; Cesar Ruiz Garcia; Francisco Rivas-Ruiz; Julio Romero-Gonzalez; Jose L Moreno; Vicente Faus; Guadalupe del Castillo Aguas; Juan C Ramos Diaz
Journal:  Trials       Date:  2009-03-10       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.